'Well-Established' Eye Health Company Bausch + Lomb Gets Outperform Rating From This Analyst
RBC Capital markets initiated coverage on Bausch + Lomb Corp (NYSE: BLCO) with an Outperform rating and a $22 price target.
The analysts see B+L as a diversified ophthalmology company with strong brand equity, reaping the rewards of over $2 billion of investment since 2018 through several new product launches and expected margin improvement.
The company is a well-established eye health company operating in the $50 billion vision care, surgical, and pharmaceutical markets.
RBC notes that some gaps in its product suite should be resolved over ~24 months, permitting B+L to better leverage its high brand equity and achieve or may exceed its targeted 4-5% revenue growth over time.
"We recognize the shares may be volatile in the near-term based on the outcome of the BHC Xifaxan patent trial (decision likely by mid-August), which will potentially influence the timing/decision regarding the expected 80% BLCO distribution by Bausch Health Companies Inc (NYSE: BHC)." RBC writes.
Price Action: BLCO shares are down 3.79% at $15.48 during the market session on the last check Tuesday.
See more from Benzinga
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
InflaRx Shares Are Flying Higher After Emergency Use Nod Plans For Its COVID-19 Treatment
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.